So I got some info today. This is information available to your neurologist and any other licensed physician if they email or talk to Biogen through their medical professionals line. It is not available to the general public or Tysabri patients anywhere that I could find.

I'll just paste what I have.

There is a chart circulating so you can go to it and figure out who is who when it comes to patient # system being used. http://pietynorwit.com/Tytable.htm

On this chart patient #4 is patient #1 after return to market, and is numbered 4(1) All of the patients listed below are post trial patients, so the number they are identified by is the one in the parentheses.

Case nos. 5, 8 and 9 all had novantrone prior to starting Tysabri. 8 and 9 were both in Sentinel, but in the Avonex plus placebo group, and likely had earlier access to restarting Tysabri than the general population.

As previously disclosed, case no. 2 was previously treated with azathioprine, and case no. 3 was previously treated with methotrexate (the latter was the US patient who died after her family reportedly decided not to follow the PML treatment protocol).

Case no. 4 had no apparent risk factors, and was described as of February 2009 as being "communicative."

Case no. 6 also had no apparent risk factors, and as of April 2009 required ventilator assistance. This appears to be the one PML patient in the poorest condition, and the only patient without apparent risk factors to contract PML after 30 months of Tysabri treatment.

Case no. 7 also had no apparent risk factors, and as of May 2009 was described as alert and ambulatory (able to walk 100 feet).

If I hear any more information I will post it here.